21014Pharmaceutical Industry for Animals
Pharmaceutical Ingredients for Animals
Last updated · Sourced from OSS Indonesia
This group includes the manufacturing and processing of medicinal materials, auxiliary materials, and packaging materials for animals, derived from chemicals, natural materials, animals, and plants, including those from biological sources, such as pharmaceuticals, antisera, and other blood fractions, vaccines, and homeopathic preparations. It also includes the industry of active pharmaceutical ingredients for pharmacological materials in the pharmaceutical industry, such as antibiotics, vitamins, salicylic acid, and o-acetylsalicylic acid, among others, blood processing, pure chemical sugar industry, gland processing industry, and gland extraction industry, among others.
KBLI 21014 at a glance
- KBLI code
- 21014
- Taxonomy version
- KBLI 2020
- Activity (English)
- Pharmaceutical Industry for Animals
- Activity (Indonesian)
- Pharmaceutical Ingredients for Animals
- Category
- Manufacturing Industry
- Risk level (Large scale, PMA)
- Medium-High
- Foreign ownership status
- Fully open to PMA (100%)
- Minimum capital (PT PMA)
- No fixed minimum, but GMP-compliant facility build typically IDR 50-100 billion+ (BPOM / Kemenkes)
- Primary licensing instrument
- NIB
- Issuing authority (PMA)
- Minister/Head of Agency
- Tax incentive eligibility
- Tax Allowance eligible
- Last verified
- April 24, 2026
Key facts for KBLI 21014
The essentials a foreign investor needs to know before reading the rest of this page.
100% foreign ownership permitted via PT PMA. KBLI 21014 is not on Indonesia's closed, conditional, SME-reserved or partnership-required schedules under Pres. Reg. 10/2021.
Default minimum paid-up capital: IDR 2.5 billion (~USD 160K) under BKPM Reg. 5/2025 (effective Oct 2025) — applies unless a sector regulator sets a higher figure for this activity. The often-cited IDR 10 billion is the total investment commitment per KBLI realised over time via quarterly LKPM reports, not required upfront.
Medium-high-risk activity — requires NIB + Standard Certificate (Verified) to operate commercially. NIB alone enables only the preparation stage; a Standard Certificate must be obtained before invoicing or production starts.
Statutory licensing turnaround: 7 days once we submit the application — on top of the 2–3 weeks for PT PMA incorporation. We coordinate the full sequence end-to-end.
Issuing authority for PMA: Minister/Head of Agency — this KBLI is routed centrally rather than to provincial / regency level.
BPOM registration mandatory: a separate Indonesian FDA marketing authorization (NIE) is required before any product is marketed. Facility must be CPOB-certified.
Ongoing reporting: quarterly LKPM (Investment Activity Report) to BKPM plus 6 sector-specific obligations. We file these on your behalf as part of monthly compliance — you stay out of the OSS portal entirely.
- Risk level
- Medium-HighNIB + verified cert.
- Primary license
- NIB + Standard Certificate (Verified)NIB enables preparation only — additional permit needed to operate
- Setup timeline
- 7 DaysStatutory turnaround at OSS
- Issuing authority
- Minister / Agency HeadDefault issuing authority
- Min. paid-up capital
- IDR 2.5 BBKPM default paid-up — sector rules may set a higher figure
Foreign investment rules
Indonesia's BUPM (Investment Business Fields) regulation places this code into one of five tracks. The track determines whether a foreign investor (PMA) can operate in this activity at all, and under what conditions.
Fully open to foreign investment
KBLI 21014 is not on Indonesia's closed, conditional, SME-reserved or partnership-required schedules. A foreign investor may incorporate a PT PMA with up to 100% foreign ownership and operate in this activity directly.
Foreign-investor tax benefits available for this KBLI under PMK 130/2020 (Tax Holiday) and PP 78/2019 (Tax Allowance). Both require approval — see the linked guide for the application path.
Note. Pharmaceutical manufacturing (KBLI 21xxx) is on the PP 78/2019 Tax Allowance priority list.
Higher minimum capital required by BPOM / Kemenkes
Pharmaceutical manufacturing (CPOB facilities)
Note. CPOB certification is the binding gate, not a flat capital number — meaningful capex needed for clean-room facility build.
BKPM Reg. 5/2025's default is IDR 2.5 billion paid-up + IDR 10 billion commitment per KBLI. The figure above is the binding override for this activity — the higher number wins.
What it costs to set up a PT PMA under KBLI 21014
Realistic year-1 cost stack for a foreign-investor PT PMA operating under this KBLI. Numbers reflect Emerhub's actual engagement scope; sector-specific overrides applied where present.
Eligible for Tax Allowance — 30% net-income reduction over 6 years.
Approximate USD equivalents at IDR 16,000/USD (Budget 2025 reference rate).
Engagement scoped to your specific business plan — exact numbers depend on operating jurisdiction, foreign-worker count, and bank choice for capital deposit.
Get an exact quote for KBLI 21014How we handle your KBLI 21014 setup
Emerhub is a corporate-services provider in Indonesia. We do the legal and regulatory legwork for foreign investors so you can focus on the business itself. Here's what the engagement looks like.
- 1
Confirm the optimal structure for your business
2–3 business daysWe confirm KBLI 21014 is the right primary code for your business, advise on secondary codes you may also need, and finalize the holding structure with you before any filing.
What we need from you- Founders' passport copies and proof of residence
- Intended share split and board composition
- 2
Incorporate your PT PMA
7–10 business daysWe draft the Articles of Association before a notary, register the entity with the Ministry of Law & Human Rights (Kemenkumham), and obtain the company's tax ID (NPWP). Under BKPM Reg. 5/2025, paid-up capital is IDR 2.5 billion (~USD 160K) — the cash actually deposited at incorporation. The IDR 10 billion+ figure many sources still cite is the total investment commitment per KBLI, realised over time via your LKPM reports.
What we need from you- Powers of attorney (we prepare; you sign and notarize)
- Director / commissioner appointment letters
- Initial capital deposit confirmation
- 3
We obtain your NIB
1–2 business daysWe file the OSS application with KBLI 21014 as your primary business activity, complete the risk-based assessment, and collect the NIB (Business Identification Number) for you — typically within hours of submission. You don't need to touch the OSS portal.
What we need from you- Office address (virtual office acceptable for many KBLIs; we can arrange one)
- 4
Secure your Standard Certificate (Verified)
7+ business daysNIB is issued for the preparation stage. To begin commercial operations, the operator must obtain a Sertifikat Standar that has been verified by the competent ministry. The verification step typically requires a site or document inspection. Operating with NIB alone is not legally compliant. We prepare the application bundle, liaise with the competent ministry, and chase issuance through to the certificate. Statutory turnaround: 7 business days — real-world timing typically runs longer when site inspections or additional clarifications are requested.
What we need from you- Technical documentation specific to your operation
- Appointment of a Penanggung Jawab Teknis (PJT — technical responsible person)
- 5
Hand-off to ongoing compliance
OngoingPost-launch we run your monthly tax filings, quarterly LKPM (Investment Activity Reports), annual general meeting (RUPS), and any sector-specific reporting. You get a single point of contact and a monthly compliance digest — no Indonesian-language paperwork on your desk.
What is KBLI 21014?
A plain-English explanation of this classification and the businesses it covers.
KBLI 21014 (Pharmaceutical Ingredients for Animals) is the 5-digit Indonesian Standard Industrial Classification code for pharmaceutical industry for animals. It sits within Manufacturing Industry under the subgroup Pharmaceutical and Chemical Medicinal Product Industry (major group 21) in the official KBLI 2020 taxonomy maintained by Statistics Indonesia (BPS).
Who needs KBLI 21014?
Any Indonesian or foreign-owned entity that intends to operate in pharmaceutical industry for animals as a primary or secondary business activity must select this code on its NIB (Business Identification Number). The selected code determines the licensing instruments required, the issuing authority, and the ongoing compliance obligations.
Why does the code matter?
Indonesia's OSS Risk-Based Approach uses the KBLI code to determine three things: (1) whether foreign investment is permitted and at what cap, (2) the risk-based licensing instruments required, and (3) the authority that issues each instrument. Choosing the wrong code can delay or invalidate your license.
Pharmaceuticals-specific guidance
Sector context that applies to KBLI 21014 beyond the generic OSS process. Verify with the relevant ministry before committing capital.
- ·CPOB (Good Manufacturing Practice) certification mandatory for all production facilities.
- ·BPOM Distribution Permit (NIE) required for each product SKU.
- ·Foreign equity in branded pharmaceuticals open up to 100%; generic drugs may have local-partner requirements.
- ·Vaccine manufacturing strategically protected; foreign participation often via JV with Bio Farma.
Under the upcoming KBLI 2025
Indonesia's BPS published the new KBLI 2025 taxonomy in early 2025. OSS, BKPM and the operating ministries have not yet adopted it — KBLI 2020 remains the active standard for business registration. This is what's coming for this specific code.
Carried forward into KBLI 2025
KBLI 21014 retains the same code number and scope in the new taxonomy. The activity description, hierarchy, and intended use of the code are preserved.
- ·Continue using 21014 for current registrations under KBLI 2020.
- ·When OSS adopts KBLI 2025 (timing not yet announced), no migration is required for this code.
- ·Risk level, permits, and authority routing shown above remain in effect under both taxonomies.
When OSS adopts KBLI 2025, we'll migrate your existing entity to the appropriate successor code as part of ongoing compliance — no action needed on your end now.
Talk to a specialistRisk level by business scale
Indonesia's OSS Risk-Based Approach assigns a separate risk level for each of the four business scales. The licensing instruments required (NIB, Standard Certificate, Operating License) are determined by the risk level. Foreign-owned entities (PT PMA) must register at the Large scale, so the rightmost column applies to most foreign investors.
Micro
Small
Medium
Large
PMA scaleWhat does each risk level require to operate? ›
Licensing requirements in detail
Specific permits, application requirements and ongoing obligations vary by business scale and the sub-activity within this KBLI. We file these on your behalf — this section is for transparency on what we'll be handling. Switch between scales below; by default we show Large (the PMA scale).
Application requirements
5Documents and capabilities you must demonstrate at registration
- 01Have a document outlining the plan for the type, specifications, quantity, and source of raw materials, as well as the source and amount/volume of energy and water needed to carry out industrial business activities for 1 (one) production cycle or for a duration of 6 (six) months ahead.
- 02Possess documents in the form of: a. Machine specifications and/or equipment list b. Photos of machines/equipment c. Sales/rental agreement that proves: 1) Control (ownership/rental) of machines for producing pharmaceutical products and quality testing equipment 2) Compliance of installed production capacity with business data
- 03Have a human resources organizational structure document that includes at least: a. Company leadership b. Production and/or quality control department c. Marketing department
- 04Have a flowchart document for: a. Procurement, receipt, and storage of raw materials b. Production process c. Quality control process d. Packaging, storage, transportation, and distribution of production results
- 05$46
Ongoing obligations
7Compliance and reporting duties throughout operation
- 01Have proof of submission of mandatory validated Industrial Data every 6 (six) months in accordance with the laws and regulations in the industrial sector.
- 02Ensure the safety and security of equipment, processes, production results, storage, and transportation, in accordance with applicable laws and regulations.
- 03Having a customer complaint/product service for: a. Adverse events b. Product quality that demonstrates a minimum service commitment to customers.
- 04Possess periodic calibration documents for quality control equipment or periodic results from independent laboratory tests on the produced products.
- 05Have a document in the form of a disaster evacuation SOP, including the arrangement of workplace safety signs.
- 06Possess a Quality Management System certificate (ISO 9001).
- 07Have a safety and security SOP for: a. Storage of raw materials in the form of chemicals b. Use of machines/equipment c. Production processes
Issuing authority
The authority that issues the license depends on your situation.
| Authority | Applies when |
|---|---|
| Minister/Head of Agency | All of them |
| Minister/Head of Agency | Foreign Investment |
Auxiliary permits (PB UMKU)
This KBLI commonly carries 8 additional permits attached to specific operational activities. PB UMKU permits are issued separately from the main business license — apply only for the ones relevant to your operation.
- Animal Drug Registration Permit (approval for changing the registration number of animal drugs)animal-drug-registration-permit-approval-for-chang
- Animal Drug Registration Permit (approval of the transfer of the animal drug registration number)animal-drug-registration-permit-approval-of-the-tr
- Animal Drug Registration Permit (emergency use approval for animal drugs)animal-drug-registration-permit-emergency-use-appr
- Animal Drug Registration Permit (re-registration)animal-drug-registration-permit-reregistration
- Certificate of Good Manufacturing Practices for Animal Drugs (CPOHB)certificate-of-good-manufacturing-practices-for-an
- Integrated Practice Permit for Veterinarians and Veterinary Paramedics (working in livestock and animal health companies) (integrated veterinary paramedic services)integrated-practice-permit-for-veterinarians-and-2
Common questions about KBLI 21014
What is KBLI 21014?
KBLI 21014 (Pharmaceutical Ingredients for Animals) is the 5-digit Indonesian Standard Industrial Classification code for pharmaceutical industry for animals. It sits within the Manufacturing Industry category in the official KBLI 2020 taxonomy maintained by Badan Pusat Statistik (BPS).
Can foreign investors operate under KBLI 21014?
Yes — KBLI 21014 is fully open to foreign investment. A PT PMA may operate with up to 100% foreign ownership, subject to BKPM Reg. 5/2025 capital requirements (IDR 2.5 billion paid-up + IDR 10 billion+ commitment per KBLI).
What is the risk level of KBLI 21014?
KBLI 21014's risk levels per business scale: Mikro Medium-High, Kecil Medium-High, Menengah Medium-High, Besar Medium-High. Foreign-owned entities (PT PMA) must register at the Large scale.
What licenses does KBLI 21014 require?
NIB only — KBLI 21014 is a low-risk activity in OSS RBA, so the Business Identification Number alone suffices for operational licensing.
What is the minimum capital for a PT PMA under KBLI 21014?
Sector regulator override: No fixed minimum, but GMP-compliant facility build typically IDR 50-100 billion+ required by BPOM / Kemenkes under PMK 26/2018 (Pelayanan Perizinan Berusaha Terintegrasi Sektor Kesehatan). This is higher than BKPM Reg. 5/2025's default IDR 2.5 billion paid-up; the higher number wins.
How long does it take to register a business under KBLI 21014?
PT PMA setup typically takes 4-8 weeks: AHU registration (1-2 weeks), NIB issuance via OSS (immediate to 1 week), bank account opening (2-4 weeks). The licensing cycle for KBLI 21014 specifically takes 7 days at the Large business scale.
Is KBLI 21014 eligible for Indonesian tax incentives?
Yes — KBLI 21014 is on the Tax Allowance priority list (PP 78/2019). Eligible for 30% reduction of taxable net income over 6 years plus accelerated depreciation.
Which authority issues the KBLI 21014 license?
Authority depends on the investor profile. For PMA: Minister/Head of Agency. For domestic SME scale: typically Governor (for Provincial scope) or Regent/Mayor (Regency/City scope). Specific mapping is in §1 of this page.
What other permits beyond the NIB does KBLI 21014 need?
Beyond the NIB, KBLI 21014 commonly requires: Animal Drug Registration Permit (approval for changing the registration number of animal drugs), Animal Drug Registration Permit (approval of the transfer of the animal drug registration number), Animal Drug Registration Permit (emergency use approval for animal drugs), Animal Drug Registration Permit (re-registration), Certificate of Good Manufacturing Practices for Animal Drugs (CPOHB), +3 more. The auxiliary permits list (PB UMKU) shown on this page is the complete set OSS associates with this code.
What KBLI codes are similar to 21014?
KBLIs in the same subgroup 2101: 21011 (Pharmaceutical Materials Industry for Humans); 21012 (Pharmaceutical Products Industry for Humans); 21013 (Animal Pharmaceutical Industry); 21015 (Medical Devices Industry in Subgroup 2101). These are closely related activities — see the related-codes section below for full list.
